NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required) | RFA CA 21 062

Opportunity Information: Apply for RFA CA 21 062

The NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) is a National Cancer Institute grant program meant to help highly promising postdoctoral scientists move quickly from mentored training into independent faculty careers. Its central goal is to build and sustain a strong pipeline of new, NCI-supported investigators by providing structured support during the period when a postdoc is finishing advanced training and preparing to launch an independent research program. The award targets postdoctoral researchers who already have a research doctorate and/or clinical doctoral degree and who are viewed as ready to transition without needing a long additional mentored career development period beyond what they have already completed.

The K99/R00 mechanism is designed around a clear transition point. In the first phase (the K99 mentored phase), the award supports the candidate while they remain in a postdoctoral setting, sharpening a research niche, building independence, and completing key work that positions them for the faculty job market. The second phase (the R00 independent phase) provides NCI research support after the awardee secures a tenure-track or equivalent independent faculty position. The intent is to reduce the typical funding gap that can make the move to independence difficult, giving awardees resources to establish a lab or independent research direction and to compete successfully for major independent grants.

A defining feature of this specific funding opportunity announcement is that it is intended for independent basic experimental studies involving humans. In NIH terms, the studies covered here meet the definition of a clinical trial because they prospectively assign human participants to one or more conditions, but they also meet the definition of basic research because the primary purpose is to understand fundamental biological or behavioral phenomena rather than to test a specific clinical application, product, or intervention aimed at immediate practical use. In plain language, applicants should be proposing basic science experiments that manipulate an independent variable in people and measure biomedical or behavioral outcomes in order to learn how something works at a fundamental level. This FOA aligns with NIH guidance describing "prospective basic science studies involving human participants."

This requirement also implies an important application routing rule. If an applicant is not planning to lead an independent clinical trial or basic experimental study with humans, or if the applicant mainly wants to gain experience by working on a human study led by another investigator rather than leading their own, then this is not the correct FOA. Those applicants are directed to apply under the companion announcement labeled "Independent Clinical Trial Not Allowed" (referenced in the text as RFA-CA-21-NNN). The distinction matters because NIH uses different review and oversight expectations depending on whether the applicant is proposing to independently direct a human-participant experimental study.

The opportunity explicitly encourages applications from researchers working in data science and cancer control science, signaling NCI interest in building independent investigators in areas such as advanced analytics, computational methods, population-level and behavioral factors, and interventions or strategies that influence cancer outcomes and prevention. While the announcement emphasizes these fields, the broader frame remains the development of outstanding early-stage postdoctoral researchers whose work aligns with NCI priorities and who are positioned to become competitive independent cancer researchers.

In terms of organizational eligibility, the program is broadly open across many U.S.-based institution types, including public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses, with small businesses also listed as eligible), and multiple levels of government entities (state, county, city/township, special district governments), as well as independent school districts and public housing authorities/Indian housing authorities. It also highlights additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. Foreign institutions themselves are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible; however, "foreign components" may be allowed under NIH policy definitions, meaning certain specific, justified activities performed outside the U.S. can be included when permitted by NIH grants policy.

The sponsoring agency is the National Institutes of Health (NIH), through NCI, and the opportunity is a discretionary grant. The listing is associated with CFDA 93.398. The source information provided notes an original closing date of February 28, 2022, and a creation date of November 3, 2021. No award ceiling or expected number of awards is specified in the provided excerpt, which typically means applicants would need to consult the full FOA and NIH policy documents for budget structure, project period limits, and the anticipated scale of the competition.

Overall, this FOA is best understood as a transition-to-independence award for exceptional postdoctoral researchers who are ready to lead their own basic experimental research involving human participants, and who want NCI support that bridges the move from postdoc training into an independent, tenure-track (or equivalent) faculty position while establishing a competitive cancer-focused research program.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.398.
• This funding opportunity was created on 2021-11-03.
• Applicants must submit their applications by 2022-02-28. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 21 062

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: